Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. Salazar R, et al. Among authors: libutti sk. Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14. Oncologist. 2018. PMID: 29242283 Free PMC article. Clinical Trial.
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.
Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group. Singh S, et al. Among authors: libutti sk. Neuroendocrinology. 2018;106(3):211-220. doi: 10.1159/000477585. Epub 2017 May 24. Neuroendocrinology. 2018. PMID: 28554173 Clinical Trial.
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Rajdev L, Lee JW, Libutti SK, Benson AB, Fisher GA Jr, Kunz PL, Hendifar AE, Catalano P, O'Dwyer PJ. Rajdev L, et al. Among authors: libutti sk. Invest New Drugs. 2022 Dec;40(6):1306-1314. doi: 10.1007/s10637-022-01311-w. Epub 2022 Oct 20. Invest New Drugs. 2022. PMID: 36264382 Free PMC article. Clinical Trial.
Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.
Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR Jr. Varghese S, et al. Among authors: libutti sk. Cancer. 2011 Jan 15;117(2):361-71. doi: 10.1002/cncr.25555. Epub 2010 Sep 13. Cancer. 2011. PMID: 20839315 Free PMC article.
The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.
Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. Howe JR, et al. Among authors: libutti sk. Pancreas. 2020 Jan;49(1):1-33. doi: 10.1097/MPA.0000000000001454. Pancreas. 2020. PMID: 31856076 Free PMC article.
Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome.
Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, Liu Y, Venzon D, Turkbey I, Choyke P, Yao J, Libutti SK, Nilubol N, Linehan WM, Kebebew E. Weisbrod AB, et al. Among authors: libutti sk. J Am Coll Surg. 2014 Feb;218(2):163-9. doi: 10.1016/j.jamcollsurg.2013.10.025. Epub 2013 Nov 12. J Am Coll Surg. 2014. PMID: 24440063 Free PMC article.
326 results